Anteris Technologies Global (NASDAQ:AVR) versus Zynex (NASDAQ:ZYXI) Financial Analysis

Zynex (NASDAQ:ZYXI – Get Free Report) and Anteris Technologies Global (NASDAQ:AVR – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Volatility & Risk

Zynex has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. Comparatively, Anteris Technologies Global has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500.

Institutional & Insider Ownership

29.7% of Zynex shares are owned by institutional investors. 49.3% of Zynex shares are owned by company insiders. Comparatively, 4.5% of Anteris Technologies Global shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Zynex and Anteris Technologies Global”s top-line revenue, earnings per share (EPS) and valuation.

Zynex has higher revenue and earnings than Anteris Technologies Global. Anteris Technologies Global is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Zynex and Anteris Technologies Global, as reported by MarketBeat.

Anteris Technologies Global has a consensus price target of $16.00, indicating a potential upside of 83.49%. Given Anteris Technologies Global’s stronger consensus rating and higher probable upside, analysts plainly believe Anteris Technologies Global is more favorable than Zynex.

Profitability

This table compares Zynex and Anteris Technologies Global’s net margins, return on equity and return on assets.

About Zynex

(Get Free Report)

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

About Anteris Technologies Global

(Get Free Report)

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.